Danny Crawford

Senior Director, Early-Stage Process Development at Intellia Therapeutics

Speaker

Danny Crawford is Senior Director in Process Development at Intellia Therapeutics, where he has spent the past 8 years advancing CRISPR-based gene editing therapies. Dr. Crawford has led key development efforts for Ziclumeran, the Cas9 mRNA component of Intellia's Phase 3 candidates, NTLA2001 and NTLA2002. He oversees integrated teams developing processes across nucleic acid therapeutics, cell therapy, and viral vector manufacturing platforms. With more than 20 years of biotechnology experience, Dr. Crawford's expertise spans process and analytical development, technology transfer, CDMO management, and guiding programs from research through clinical development. He holds a PhD in Biochemistry from Brandeis University and has contributed to multiple patents in nucleic acid therapeutics